Atrial cardiomyocytes appear to have the remarkable capacity to divide in many adult vertebrate hearts including mammals during cardiac ventricular injury^[@R7],[@R8]^; however, it remains unclear as to the role of these proliferating atrial cardiomyocytes. To address this issue, we have generated in the zebrafish, a genetic cardiac ventricle-specific nitroreductase (NTR)-mediated ablation system^[@R9]^, *Tg(vmhc:mCherry-NTR)^s957^*, using the *ventricular myosin heavy chain (vmhc)* promoter^[@R10]^. Thus, this ablation system permits the targeted destruction of ventricular cardiomyocytes after metronidazole (MTZ) treatment ([Fig. 1](#F1){ref-type="fig"}). Furthermore, to track both atrial and ventricular cardiomyocytes during ventricular injury, we have fused the mCherry fluorescent protein to NTR to label ventricular cardiomyocytes in red (vCherry) as well as used the *atrial myosin heavy chain (amhc)* promoter to create the *Tg(amhc:eGFP)^s958^* transgenic line, which marks atrial cardiomyocytes in green (aGFP). As a result, we observed that the expression of mCherry and GFP in these reporter lines were restricted to ventricular and atrial cardiomyocytes, respectively throughout development ([Supplementary Fig. 1a--d](#SD3){ref-type="supplementary-material"}). In order to visually monitor *in vivo* the dynamic cellular events that transpire throughout ventricular injury and regeneration within the same animal, the ventricles of *Tg(vmhc:mCherry-NTR);Tg(amhc:eGFP)* hearts were ablated at 3--4 days post-fertilization (dpf), an age when the zebrafish heart has completed cardiac looping and cardiac chamber cardiomyocytes have fully differentiated^[@R11]^, but the zebrafish remains optically clear. As a result, 4 dpf ablated *vmhc:mCherry-NTR* ventricles displayed significant reduction in vCherry fluorescence by 24 hours post MTZ treatment (hpt) ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 2a](#SD3){ref-type="supplementary-material"}). This rapid decrease in vCherry fluorescence was accompanied by a reduction in ventricular size ([Fig. 1b](#F1){ref-type="fig"}, [Supplementary Fig. 2b](#SD3){ref-type="supplementary-material"}) and function (fractional area change decreased from 42% to 16% at 24 hpt/N=5, *p*=0.004; [Supplementary videos 1](#SD4){ref-type="supplementary-material"}, [2](#SD5){ref-type="supplementary-material"}; [Supplementary Fig. 3a--c](#SD3){ref-type="supplementary-material"}), leading to pericardial edema and overall decreased blood circulation. TUNEL cell death assays revealed that this decrease in ventricular function and size was due to an increase in ventricular cardiomyocyte death ([Fig. 1f](#F1){ref-type="fig"}). Conversely, we observed that the atria significantly enlarged ([Supplementary Fig. 2b](#SD3){ref-type="supplementary-material"}) and maintained normal contractile function ([Supplementary Fig. 3d](#SD3){ref-type="supplementary-material"}) during this reduction in ventricular size and function.

By 48 hpt, we observed in these injured ventricles an accretion of new vCherry^+^ cardiomyocytes adjacent to the atrioventricular canal (AVC) ([Fig. 1c](#F1){ref-type="fig"}, asterisk), which continued to expand across the ventricle over the next 48 hours to restore lost ventricular myocardium nearest the AVC by 96 hpt ([Fig. 1d](#F1){ref-type="fig"}, asterisk). Subsequently, ventricular cardiac function recovered in these injured hearts to nearly that of age-matched controls by 96 hpt (fractional area change of ablated and control ventricle was 38% and 39%, respectively; N=5, *p*=0.49; [Supplementary Fig. 3c](#SD3){ref-type="supplementary-material"}), allowing for survival of these ventricle-ablated fish into adulthood. Anti-phospho-histone H3 immunostaining revealed that ventricular injury resulted in not only ventricular but also atrial cardiomyocyte proliferation ([Fig. 1g, h](#F1){ref-type="fig"}; [Supplementary Fig. 4](#SD3){ref-type="supplementary-material"}), as observed in other cardiac injury and regeneration models^[@R4],[@R6],[@R12]^. Although this cardiomyocyte cell division peaked by 48 hpt in both cardiac chambers ([Supplementary Fig. 4d, e](#SD3){ref-type="supplementary-material"}), there was a particularly significant atrial cardiomyocyte proliferative increase that remained elevated up to 84 hpt.

During the ventricular recovery, we observed the presence of low expressing aGFP cardiomyocytes (aGFP^lo^) within the injured ventricle near the AVC between 24--48 hpt ([Fig. 1b, c](#F1){ref-type="fig"}, [2b](#F2){ref-type="fig"}), whereas aGFP cardiomyocytes were never observed in the ventricle of control hearts ([Fig. 2a](#F2){ref-type="fig"}). Optical sections of the AVC region revealed that these aGFP^lo^ cardiomyocytes co-expressed the vCherry marker in the ablated ventricles ([Fig. 2b](#F2){ref-type="fig"}', arrowheads), but were not detected in unablated ventricles ([Fig. 2a](#F2){ref-type="fig"}'). To further confirm these findings, we examined the gene expression of *amhc* and *vmhc* in the hearts of these ablated ventricles and observed that *amhc* was expressed throughout the atrium and frequently in the ventricle at the AVC by 24--48 hpt, where we observed the double labeled aGFP^lo^;vCherry cardiomyocytes; whereas, *vmhc* was expressed throughout the ventricle but rarely in the atrium at 12--24 hpt only ([Supplementary Fig. 5](#SD3){ref-type="supplementary-material"}). Thus, these findings suggest that during injury, preexisting atrial cardiomyocytes may migrate to the ventricle to transdifferentiate into ventricular cardiomyocytes, or alternatively, proliferating dedifferentiated ventricular cardiomyocytes may need to activate an atrial program prior to fully differentiating into ventricular cardiomyocytes. Given that we still observe some proliferating pre-existing vCherry cardiomyocytes that never express the aGFP marker, we hypothesize that the atrial-to-ventricular cardiomyocyte transdifferentiation model may be more plausible.

To further investigate this transdifferentiation model, we performed genetic lineage tracing of atrial cardiomyocytes in the *Tg(vmhc:mCherry-NTR)* ventricle ablation model using an atrial cardiomyocyte specific tamoxifen-inducible Cre transgenic line, *Tg(amhc:CreERT2)^sd20^*, and the indicator transgenic line, *Tg(β-actin2:loxP-DsRed-STOP-loxP-eGFP)^s928^ (β-act2:RSG)*, which can effectively label most cells, including cardiomyocytes and endocardial cells, in GFP after tissue-specific Cre-mediated excision of the floxed dsRed cassette^[@R5],[@R13]^. Treating the *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* fish with 4-hydroxytamoxifen (4-HT) at 3 dpf for 4--6 hours, effectively GFP labeled all atrial cardiomyocytes by cre recombination (c-aGFP^+^) without ectopic GFP-labeling of ventricular cardiomyocytes by 5 dpf ([Fig. 2c, e](#F2){ref-type="fig"}; [Supplementary Fig. 6a--c](#SD3){ref-type="supplementary-material"}); whereas vehicle control treatment resulted in no cre-mediated GFP labeling of any cells ([Supplementary Fig. 6d](#SD3){ref-type="supplementary-material"}). We subsequently MTZ-ablated the ventricles of these c-aGFP-labeled hearts at 5 dpf ([Fig. 2e](#F2){ref-type="fig"}). In the ablated group, these c-aGFP^+^ cardiomyocytes at 96 hpt and at 12 months were present in not only the atrium but also in the ventricle where many of them also co-expressed vCherry (n = 73/76; [Fig. 2f](#F2){ref-type="fig"}, [Supplementary Fig. 7i, j, 8b, c](#SD3){ref-type="supplementary-material"}). However, in the control non-ablated group at 96 hpt and at 12 months, c-aGFP^+^ cardiomyocytes were only observed in the atrium but never in the ventricle (n = 0/54; [Fig. 2d](#F2){ref-type="fig"}; [Supplementary Fig. 6c, 8a](#SD3){ref-type="supplementary-material"}). Using time-lapse imaging within the same ventricle-ablated *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* hearts, we observed the gradual and contiguous extension of these c-aGFP^+^ cardiomyocytes at the AVC into the ventricle where they began to restore ventricular contractile function nearest the AVC and also to exhibit vCherry expression, suggesting that they were transdifferentiating from atrial to ventricular cardiomyocytes ([Fig. 2g--j](#F2){ref-type="fig"}, [Supplementary Videos 3](#SD6){ref-type="supplementary-material"}--[5](#SD8){ref-type="supplementary-material"}). Electrophysiologic intracellular recordings revealed that these c-aGFP^+^/vCherry^+^ cardiomyocytes within the regenerating ventricle exhibited electrical attributes similar to endogenous c-aGFP^−^/vCherry^+^ ventricular cardiomyocytes and distinct from atrial cardiomyocytes (i.e. c-aGFP^+^/vCherry^−^) ([Supplementary Fig. 9](#SD3){ref-type="supplementary-material"}). Furthermore, in situ analysis showed that the ventricular specific markers, *irx1a* and *vmhc*, were expressed in ventricular cardiomyocytes at the AVC where c-aGFP^+^ ventricular cardiomyocytes reside ([Supplementary Fig. 10](#SD3){ref-type="supplementary-material"}). Moreover, we also observed that the atrial chamber c-aGFP^+^ fluorescence intensity and size in hearts with ablated ventricles appeared to be significantly greater than that of control hearts (compare [Fig. 2f to d](#F2){ref-type="fig"}, [Supplementary Fig. 7k, l](#SD3){ref-type="supplementary-material"}), an observation consistent with the increased atrial size, fluorescence intensity, and cardiomyocyte proliferation observed after ventricular injury ([Supplementary Fig. 2a, b, 4d](#SD3){ref-type="supplementary-material"}). Finally, in adult zebrafish ventricles ablated at 4 months, we discovered that the contribution of transdifferentiated atrial cardiomyocytes to the regenerating ventricle was diminished ([Supplementary Fig. 11](#SD3){ref-type="supplementary-material"}), suggesting that this cardiac transdifferentation process may be age-dependent.

To investigate whether these atrial-derived ventricular cardiomyocytes maintained the atrial program, we examined Amhc protein expression by S46 immunostaining in the ventricle-ablated *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* hearts, and observed that c-aGFP^+^ atrial cardiomyocytes continued to express Amhc in the atrium ([Fig. 2m, n](#F2){ref-type="fig"}), but not in the ventricle. However, prior to their subsequent differentiation into ventricular cardiomyocytes (c-aGFP^+^, Amhc/S46^−^, vCherry^+^, [Fig. 2n](#F2){ref-type="fig"}, [Supplementary Fig. 7d](#SD3){ref-type="supplementary-material"}, d' asterisk), we discovered that c-aGFP^+^ cardiomyocytes may first exist in an intermediate dedifferentiation stage (c-aGFP^+^, Amhc/S46^−^, vCherry^−^, [Fig. 2n](#F2){ref-type="fig"}, [Supplementary Fig. 7d](#SD3){ref-type="supplementary-material"}, d' arrowheads), where they no longer maintain the atrial program (Amhc/S46^−^) but have not yet activated the ventricular program (vCherry^−^). Consistent with these findings, *vmhc* fluorescent *in situ* hybridization also revealed a population of c-aGFP^+^ cardiomyocytes devoid of *vmhc* expression within the recovering ventricle ([Fig. 2r](#F2){ref-type="fig"}, [Supplementary Fig. 7h](#SD3){ref-type="supplementary-material"}, h' arrowheads). Because of this possible dedifferentiation of atrial cardiomyocytes, we also examined the expression of cardiac progenitor markers in the ventricle-ablated hearts. Although we did not detect Isl1 in the injured hearts (data not shown), we did observe the re-expression of *gata4, hand2, nkx2.5, tbx5* and *tbx20* ([Supplementary Fig. 12](#SD3){ref-type="supplementary-material"}) as well as increased expression of Mef2 in the atrium, ventricle, and outflow tract of the recovering ventricle-ablated hearts ([Supplementary Fig. 13](#SD3){ref-type="supplementary-material"}). Furthermore, Mef2 immunofluorescence revealed not only that many of the intermediate dedifferentiated c-aGFP^+^ cardiomyocytes within the recovering ventricle (i.e. c-aGFP^+^/vCherry^−^) expressed Mef2 ([Supplementary Fig. 13](#SD3){ref-type="supplementary-material"}p', arrowheads), but also that the new Mef2^+^ cells at the outflow tract did not express myosin heavy chain ([Supplementary Fig. 13e--h](#SD3){ref-type="supplementary-material"}), suggesting that these cells may be cardiac progenitor cells, which have not yet differentiated into mature cardiomyocytes. Overall, these data suggest that atrial cardiomyocytes may acquire cardiac progenitor cell attributes to become ventricular cardiomyocytes and moreover that the zebrafish second heart field residing near the outflow tract^[@R14],[@R15]^ may also contribute ventricular cardiomyocytes to recover the distal portion of the injured ventricle.

To further elucidate the cellular events that take place during ventricular injury and recovery including the atrial-to-ventricular cardiac lineage switch, we analyzed the cardiomyocyte structural and morphologic changes after ventricular ablation. To this end, we crossed the *Tg(vmhc:mCherry-NTR)* fish to the reporter lines, *Tg(cmlc2:actinin-eGFP)^sd10^* or *Tg(cmlc2:eGFP-ras)^s883^*, which labels sarcomeric structures^[@R16]^ or outlines cardiomyocytes^[@R17]^, respectively ([Fig. 3a--j](#F3){ref-type="fig"}, [Supplementary Fig. 14](#SD3){ref-type="supplementary-material"}), as well as performed N-cadherin immunostaining to examine cardiomyocyte cell-cell junctions ([Fig. 3k--o](#F3){ref-type="fig"}). During ventricular injury, damaged ventricular cardiomyocytes lost their rod-like shape^[@R18]^, particularly at the outer curvature ([Fig. 3g, h](#F3){ref-type="fig"}, asterisks), and as reported^[@R4],[@R5]^, exhibited disorganized or complete loss of sarcomeres and cell junctions between 12--24 hpt ([Fig. 3b, c, l, m](#F3){ref-type="fig"}, asterisks), when ventricular function has reached its nadir. In contrast, during ventricular recovery (36--48 hpt), we observed the reorganization of not only ventricular but also atrial cardiomyocyte sarcomeres, morphologies, and adhesion junctions, ([Fig. 3d, i, n](#F3){ref-type="fig"}, [Supplementary Fig. 14e](#SD3){ref-type="supplementary-material"}). In particular, atrial cardiomyocytes at the AVC became more circular ([Supplementary Fig. 14b, e](#SD3){ref-type="supplementary-material"}) and lost N-cadherin localization at their cell junctions when they began to extend into the ventricle and differentiate into ventricular cardiomyocytes ([Fig. 3n](#F3){ref-type="fig"}). Moreover, we also observed that these migrating atrial cardiomyocytes at the AVC initially displayed disorganized sarcomeric structures ([Supplementary Fig. 14d](#SD3){ref-type="supplementary-material"} asterisk), but after populating the ventricle, exhibited enriched actinin-eGFP at the cell periphery/cortex ([Fig. 3d](#F3){ref-type="fig"}, [Supplementary Fig. 14d](#SD3){ref-type="supplementary-material"} - box, d' - arrow) and frequently short bundles of actinin-eGFP labeled z-line structures ([Fig. 3d](#F3){ref-type="fig"}, [Supplementary Fig. 14d](#SD3){ref-type="supplementary-material"}', arrowhead), closely resembling *de novo* sarcomere assembly^[@R16]^. By 96 hpt when the ventricle has functionally recovered, the ventricular cardiomyocytes derived from reprogrammed atrial cardiomyocytes exhibited not only organized sarcomeres that align with other ventricular cardiomyocytes but also localization of N-cadherin at the cell junctions ([Fig. 3e, o](#F3){ref-type="fig"}). Overall, these results reveal that atrial cardiomyocytes undergo activated cellular reprogramming following ventricular myocardial injury in order to initiate cellular events that permit their proliferation, migration, and transdifferentiation to facilitate ventricular regeneration.

Because previous studies have shown that endocardial activation may be essential to regulate cardiac regeneration^[@R19]^, we examined Raldh2 expression in ventricle ablated *Tg(vmhc:mCherry-NTR)* fish. Although Raldh2 is expressed weakly in control treated hearts ([Supplementary Fig. 15a, c, g, h](#SD3){ref-type="supplementary-material"}), its expression is induced throughout the endocardium of the ventricle-ablated hearts by 24--48 hpt ([Supplementary Fig. 15b, d, k, l](#SD3){ref-type="supplementary-material"}). Using the *Tg(tp1:eGFP)^um14^* Notch reporter line^[@R20]^, we also observed that Notch signaling (i.e. *tp1*:eGFP expression) was specifically activated in atrial endocardial cells of *Tg(vmhc:mCherry-NTR)* MTZ-ablated hearts, as detected by the overlapping expression between *tp1*:eGFP and *kdrl*:mCherry (*Tg(kdrl:ras-mCherry)^s896^*), which labels endothelial/endocardial cell membranes in red^[@R21]^ (compare [Fig. 4a to b, 4e to f](#F4){ref-type="fig"}). Whole mount *in situ* hybridization of Notch signaling components revealed that *notch1b* and *deltaD*, which are normally present in the AVC and OFT of uninjured hearts ([Fig. 4i, m](#F4){ref-type="fig"}), exhibited increased AVC expression as well as activated atrial expression in ventricular-ablated hearts ([Fig. 4j, n](#F4){ref-type="fig"}); however, *deltaC* was absent ([Supplementary Fig. 16](#SD3){ref-type="supplementary-material"}). Because *tp1*:eGFP expression was strong in the ventricle ([Fig. 4a, b](#F4){ref-type="fig"}), but *notch1b* and *deltaD* expression was not, we performed *gfp* RNA in situ analysis to confirm this *tp1*:eGFP ventricular fluorescence and discovered that *gfp* RNA expression was weak to negligible in both uninjured and injured ventricles ([Supplementary Fig. 17a, b](#SD3){ref-type="supplementary-material"}), suggesting that the relatively robust *tp1*:eGFP ventricular fluorescence may be due to eGFP protein perdurance. Finally, we investigated whether these Notch-activated atrial endocardial cells genetically marked by *Tg(kdrl:Cre)^s898^;Tg(β-act2:RSG)*^[@R13]^ could reprogram into cardiomyocytes to contribute to the regeneration of the ventricle-injured heart, but found no evidence for such an event (data not shown). Conversely, we did not observe any of the genetically marked atrial cardiomyocytes (c-aGFP^+^) becoming endocardial cells ([Supplementary Fig. 15i--l](#SD3){ref-type="supplementary-material"}).

Thus, to further investigate the significance of this injury-induced atrial Notch activation, we treated ventricle-ablated hearts with the γ-secretase inhibitor, DAPT. As a result, DAPT treatment significantly decreased the ability of these hearts to restore their ventricular morphology and function after injury (control 81%, N=96/119 vs. DAPT-treated 39%, N=52/132; [Fig. 4h](#F4){ref-type="fig"}), which may be due to overall decreased atrial and ventricular cardiomyocyte proliferation ([Supplementary Fig. 18](#SD3){ref-type="supplementary-material"}). To determine how DAPT impairs this recovery process, we examined the expression of *tp1*:eGFP as well as the migration of genetically labeled atrial cardiomyocytes in DAPT-treated ventricle-injured hearts. We observed not only decreased *tp1*:eGFP expression in the atrium ([Fig. 4d](#F4){ref-type="fig"}) but also a reduction in the migration of c-aGFP^+^ atrial cardiomyocytes into the injured-ventricle ([Fig. 4g](#F4){ref-type="fig"}). Consistent with these findings, DAPT also inhibited *notch1b, deltaD*, and *tp1:egfp* expression in the atrium of ventricle-injured hearts ([Fig. 4l](#F4){ref-type="fig"}, p, [Supplementary Fig. 17d](#SD3){ref-type="supplementary-material"}), but interestingly increased *notch1b* and *deltaD*, in the OFT of uninjured hearts ([Fig. 4k, o](#F4){ref-type="fig"}). Thus, these data suggest that atrial endocardial Notch activation may be crucial to non-cell-autonomously regulate ventricle regeneration through the modulation of atrial-to-ventricular transdifferentiation.

Overall, these results reveal that *in vivo* reprogramming of differentiated atrial cardiomyocytes can be induced by cardiac ventricular injury through Notch-mediated signaling and proceeds in distinct intermediate stages ([Supplementary Fig. 19](#SD3){ref-type="supplementary-material"}) in order to provide a novel endogenous cellular source for cardiac ventricular regeneration in zebrafish. Similar to recent cardiac-injury studies in zebrafish and mouse neonatal hearts, this process may be mediated through the activation of Raldh2 and Notch pathways^[@R19],[@R22]^, which may lead to sarcomeric reorganization^[@R4],[@R5]^, cardiomyocyte migration^[@R4],[@R5]^, and the re-expression of key early cardiac transcriptional regulators, such as Gata4, Hand2, Mef2, Nkx2.5, Tbx5, and Tbx20^[@R5],[@R6],[@R23]^. Although Raldh2 was expressed throughout the endocardium of the ventricle-injured heart as previously described^[@R6],[@R19]^, Notch signaling was activated primarily in the atrial endocardium. As a result, we speculate that Notch-activated atrial endocardium may influence the atrial myocardium, just as Notch signaling in the ventricular endocardium influences ventricular trabeculation^[@R24]^. Given that previous studies have shown that specific congenital heart diseases can arise from aberrant Notch signaling^[@R25]^, our studies also raise the possibility that abnormal reprogramming of cardiac lineages may be partially responsible for these heart defects.

Though it remains to be elucidated whether mammalian atrial cardiomyocytes may also have a comparable transdifferentiation capacity, recent studies have indicated that mammalian cardiomyocyte progenitor cells (CPMCs) appear to be enriched in the atrium^[@R26]--[@R28]^ suggesting that the zebrafish transdifferentiating atrial cardiomyocytes may be analogous to the atrial-resident adult CPMCs. Alternatively, mammalian atrial cardiomyocytes could reprogram into ventricular cardiomyocytes through the reactivation of early cardiac transcriptional factors, which has been recently reported to reprogram cardiac fibroblasts into ventricular cardiomyocytes in mouse hearts^[@R29],[@R30]^. Thus, future studies in mammalian ventricular injury models^[@R6]^ using similar atrial genetic lineage tracing strategies as presented here, are warranted to further investigate the potential of this cardiac reprogramming process as an endogenous cellular regenerative therapy in human heart failure patients. Such a cardiac regenerative strategy could overcome current obstacles facing the translation of stem cell therapies for heart failure patients, including the differentiation of autologous cardiac progenitor cells into ventricular cardiomyocytes as well as the delivery and integration of these differentiated ventricular cardiomyocytes into the patient's ventricular myocardium.

Methods Summary {#S1}
===============

Chamber-specific ablation and reporter lines were generated using the standard I-*Sce*I meganuclease transgenesis technique (details in Methods). To perform ventricular cardiomyocyte ablation, *Tg(vmhc:mCherry-NTR)* zebrafish were treated with 5 mM MTZ as previously described^[@R9]^. For lineage tracing experiments, *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* zebrafish were treated with 10 µM 4-hydroxytamoxifen as previously described^[@R5]^. For Notch inhibition studies, zebrafish were treated with 100 µM DAPT. Live imaging, heart contraction, immunofluorescence, and whole mount *in situ* hybridization were performed as described in Methods.

Methods {#S2}
=======

Zebrafish husbandry and generation of transgenic fish lines {#S3}
-----------------------------------------------------------

Zebrafish were raised under standard laboratory conditions at 28°C. We used the following transgenic lines: *Tg(β-actin2:loxP-DsRed-STOP-loxP-eGFP)^s928^ - Tg(β-act2:RSG)*^[@R5]^, *Tg(cmlc2:actinin-eGFP)*^*sd10*\ (16)^, *Tg(cmlc2:eGFP-ras)*^*s883*(17)^, *Tg(tp1:eGFP)*^*um14*(20)s^, *Tg(kdrl:ras-mCherry)*^*s896*(21)^ and *Tg(kdrl:Cre)*^*s898*(13)^. The *Tg(tp1:eGFP)^um14^* notch reporter line used for these studies was previously confirmed for reporting notch activity in the heart as well as other tissues using the mindbomb mutant^[@R25],[@R31],[@R32]^. The construct to create *Tg(vmhc:mCherry-NTR)^s957^* was generated by cloning a 2 kb *vmhc* promoter^[@R10]^ into the pBSKi vector^[@R33]^, and the mCherry-nitroreductase fusion gene was then cloned downstream of the *vmhc* promoter. The construct to create *Tg(amhc:eGFP)^s958^* was generated by cloning a 982 bp *amhc* promoter (forward primer: 5'-gctaaagtggcagtgtgccg and reverse primer: 5'-cgtgaatatggttttcaggag) into the pBSKi vector, and GFP was cloned downstream of the *amhc* promoter. The construct to create *Tg(amhc:CreERT2)^sd20^* was generated by cloning a 4.5 kb *amhc* promoter (forward primer: 5'-cctggaactcaacaatgctc and reverse primer: 5'-gatctggatctctcctcagttg) into the pBSKi vector, and CreERT2^[@R34]^ was cloned downstream of the *amhc* promoter. We injected 200 pg of each linearized DNA into one-cell-stage embryos and selected individual transgenic carrier adults by screening for fluorescent progeny.

MTZ treatment {#S4}
-------------

*Tg(vmhc:mCherry-NTR)* larval and adult zebrafish were treated with 5 or 10 mM MTZ in egg or zebrafish system water for four hours and two days, respectively at 28°C in the dark as previously described^[@R35]^. As controls, age-matched *Tg(vmhc:mCherry-NTR)* siblings were incubated in 0.2% DMSO in egg or zebrafish system water. Treated zebrafish were washed with several changes of fresh egg or zebrafish system water at the end of ablation and then allowed to continue to grow in fresh egg or zebrafish system water.

TUNEL {#S5}
-----

Using the *in situ* cell death detection kit, fluorescein from Roche (\#11684795910), fish hearts were examined for cell death by TUNEL staining. Specifically, zebrafish at the indicated stages were fixed with 4% PFA, permeabilized with PBS/0.5% TritonX-100 and then incubated in TUNEL staining solution at 37°C for 2 hours.

Immunofluorescence {#S6}
------------------

Immunofluorescence staining was performed as previously described^[@R36]^. The primary antibodies used in this study include: anti-GFP (chicken; Aves Labs), anti-Isl^[@R11]^ (mouse; Developmental Studies Hybridoma Bank), anti-Mef2/C-21^[@R15]^ (rabbit; Santa Cruz Biotechnology), MF20/anti-MHC^[@R37]^ (mouse; Developmental Studies Hybridoma Bank), anti-N-cadherin^[@R38]^ (rabbit; courtesy of Dr Q. Liu), anti-phospho-histone H3 (rabbit; Upstate), anti-Raldh2^[@R19]^ (rabbit; Abmart), and S46/anti-Amhc^[@R37]^ (mouse; Developmental Studies Hybridoma Bank). For the *vmhc* fluorescent *in situ* hybridization studies, GFP antibody was used to detect the GFP genetically labeled atrial cardiomyocytes. Raldh2 antibody was used to examine endocardial and epicardial activation during cardiac injury^[@R19]^. The secondary antibodies used in this study include: Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 594 goat anti-mouse IgG, Alexa Fluor 633 goat anti-mouse IgG, and Alexa Fluor 647 goat anti-rabbit IgG from Invitrogen, and Anti-chicken IgY-FITC from Sigma. Fluorescent images were obtained using a Leica SP5 or Nikon C2 confocal microscope.

*in situ* hybridization {#S7}
-----------------------

Whole mount *in situ* hybridization was performed as previously described^[@R18]^, using the following probes: *amhc, deltaC* (courtesy of Dr J. Lenis), *deltaD* (courtesy of Dr W. Clements), *gata4, gfp, hand2, irx1a, nkx2.5, notch1b* (courtesy of Dr M. Lardelli), *tbx5, tbx20*, and *vmhc. vmhc* fluorescent *in situ* hybridization^[@R37]^ was performed as previously described^[@R39]^ using single digoxygenin-labeled riboprobe and detected by TSA Plus Cy5 Solution (Perkin Elmer).

Cardiac contractile analysis {#S8}
----------------------------

Live zebrafish were embedded in 1% low melting agarose in a glass bottom culture dish (MatTek), and the heart contraction was recorded by a high speed EMCCD camera (Hamamatsu). The heart function was analyzed as previously described^[@R40]^. The fractional area change was calculated as FC = (End diastolic area -- End systolic area)/End diastolic area \* 100%.

Intracellular action potential recording {#S9}
----------------------------------------

Adult zebrafish hearts were mounted in a chamber containing Tyrode's solution of the following composition (mM): NaCl 150, KCl 5.4, MgSO~4~ 1.5, NaH~2~PO~4~ 0.4, CaCl~2~ 2, Glucose 10, HEPES 10. The pH of the solution was adjusted to 7.4 with NaOH. Glass pipettes with tip resistance 30--40 MΩ were filled with 3M KCl solutions. The hearts were allowed to equilibrate for 10 min before spontaneous intracellular action potentials were recorded using an Axopatch 200B amplifier and pClamp10.3 software (Molecular Devices, LLC). Electrophysiologic intracellular recordings were performed on transdifferentiated ventricular cardiomyocytes (c-aGFP^+^/vCherry^+^), endogenous ventricular cardiomyocytes (c-aGFP^−^/vCherry^+^) and atrial cardiomyocytes (c-aGFP^+^/vCherry^−^). All experiments were performed at room temperature (20--22°C). N=5 hearts.

Tamoxifen treatment and lineage tracing {#S10}
---------------------------------------

*Tg(vmhc:mCherry-NTR;amhc:CreERT2; β-act2:RSG)* zebrafish were treated with 10 µM 4-Hydroxytamoxifen (4-HT) solution (Sigma) or 0.1% ethanol alone (control) at 72 hpf for 6 h at 28°C and then washed with fresh egg water several times. The ventricles of hearts with GFP genetically labeled atrial cardiomyocytes were then ablated at 96--120 hpf (n = 76) or at 4 months (n = 23). Live zebrafish were embedded in 0.5% low melting agarose in a glass bottom culture dish as previously described^[@R41]^ for time lapse imaging using a Leica M205FA stereomicroscope with a DFC310FX camera. The hearts were then collected at indicated time points post treatment, cryo-sectioned and examined under a Nikon C2 confocal microscope.

Cryosection and histology staining {#S11}
----------------------------------

Adult zebrafish hearts were fixed in 4% PFA for two hours at room temperature and equilibrated through 15% and then 30% sucrose in PBS for several hours until they sank down to the bottom. Hearts were embedded in O.C.T. compound (Tissue-Tek, 4583) and frozen in liquid nitrogen. 10 µm cryosections were prepared on a Leica CM3050 S cryostat. Masson's trichrome staining was performed using the Sigma HT15 kit.

DAPT treatment {#S12}
--------------

Zebrafish were incubated in egg water with 100 µM DAPT (Sigma) or 0.1% DMSO alone (control) right after ablation until the zebrafish were fixed or examined at indicated stages. Treated zebrafish were washed several times in egg water after DAPT or DMSO treatment.

Quantification and statistical analysis {#S13}
---------------------------------------

To measure cardiac chamber size, *Tg(vmhc:mCherry-NTR)* hearts were visualized by bright field microscopy at the indicated conditions, and the cardiac chamber size was calculated by measuring the surface area of outlined chambers using Leica LAS AF software (N=10). To determine average fluorescence intensity for each chamber, *Tg(vmhc:mCherry-NTR; cmlc2:actinin-eGFP)* hearts were visualized by confocal microscopy at the indicated stages, and average fluorescence intensity was calculated by measuring the fluorescence intensity of outlined maximal projections of cardiac chambers using Nikon NIS Elements software (N=5). Cardiomyocyte surface area and circularity were measured by outlining single cardiomyocytes on confocal maximal projection images of *Tg(vmhc:mCherry-NTR; cmlc2:eGFP-ras)* hearts using the Nikon NIS Elements software (N=15, 5 cells per heart, 3 hearts) as previously described^[@R18]^. Circularity is calculated as Circularity = 4 \*π\* Area / Perimeters^[@R2]^. To determine the percentage of the *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* ventricles that is GFP positive, the measured GFP positive surface area of the cardiac ventricles as detected by confocal microscopy was divided by the measured total surface area of the cardiac ventricles as detected by brightfield microscopy. To determine the surface area and average fluorescence intensity of the *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* atria, the atrial chamber surface area and fluorescence were measured in the bright field and GFP channel using the Nikon NIS Elements software (N=5). *p* values were obtained by unpaired two-tailed Student\'s *t*-test.
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![Genetic ventricular-specific cardiomyocyte ablation results in ventricular cardiomyocyte death and subsequent regeneration\
(a--d) Metronidazole (MTZ)-ablated *Tg(vmhc:mCherry-NTR;amhc:eGFP)* ventricular cardiomyocytes at (a) 0, (b) 24, (c) 48, (d) 96 hours post-treatment (hpt). Red - ventricular cardiomyocytes; Green - atrial cardiomyocytes; Asterisks - AVC. (e, f) TUNEL staining (green) in 24 hpt *Tg(vmhc:mCherry-NTR)* (e) control and (f) ablated ventricles (red) at 4 dpf. Blue - DAPI. (g, h) Anti-phospho-histone H3 staining (magenta) in 48 hpt *Tg(vmhc:mCherry-NTR;cmlc2:actinin-eGFP)* (g) control and (h) ablated hearts (green) at 5 dpf. Arrowheads - anti-phospho-histone H3 positive cells. A - atrium; V - ventricle.](nihms484742f1){#F1}

![In vivo cardiac reprogramming contributes to zebrafish ventricular regeneration\
(a, b) 32 hpt *Tg(vmhc:mCherry-NTR;amhc:eGFP)* (a) control and (b) ablated hearts. (a', b') AVC section of a and b. Arrowheads - mCherry^+^/GFP^+^ cardiomyocytes. (c--j) 4-HT-treated *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* zebrafish in (c, d) control or (e--j) ablated hearts at (c, e) 0, (g) 32, (h) 48, (i) 64, (j) 80, (d, f) 96 hpt. (g--j) 32--80 hpt GFP time-lapse imaging. (k--r) 4-HT-treated *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* ablated hearts at 96 hpt. (k) red - vCherry^+^; (l, p) green - c-aGFP^+^; (m, q) magenta - S46/anti-Amhc; (n, r) merge; and (o) blue - *vmhc* RNA. Asterisk - (n) vCherry^+^/c-aGFP^+^/S46^−^, (r) *vmhc*^+^/c-aGFP^+^/S46^−^ ventricular cardiomyocytes. Arrowhead - (n) vCherry^−^/c-aGFP^+^/S46^−^, (r) *vmhc*^−^/c-aGFP^+^/S46^−^ ventricular cardiomyocytes. A - atrium; V - ventricle. Dashed lines - atrioventricular boundary.](nihms484742f2){#F2}

![Dynamic cellular remodeling occurs during zebrafish cardiac regeneration\
MTZ-treated (a--e) *Tg(vmhc:mCherry-NTR;cmlc2:actinin-eGFP)*; (f--j) *Tg(vmhc:mCherry-NTR;cmlc2:eGFP-ras)*; and (k--o) N-cadherin immunostained *Tg(vmhc:mCherry-NTR)* zebrafish. (a, f, k) 0 hpt; (b, g, l) 12 hpt; (c, h, m) 24 hpt; (d, i, n) 48 hpt; (e, j, o) 96 hpt. Asterisks - ventricular cardiomyocyte injury and death due to ablation. Dashed lines - outer curvature ventricular cardiomyocytes. Inset - enlargement of boxed area in k-o at AVC. A - atrium; V - ventricle.](nihms484742f3){#F3}

![Notch signaling is required for zebrafish cardiac regeneration\
(a--d) 30 hpt *Tg(vmhc:mCherry-NTR;tp1:eGFP)* (a) control; (b) ablated; (c) DAPT-treated control; (d) DAPT-treated ablated hearts. (e, f) Atrium of 30 hpt *Tg(vmhc:mCherry-NTR;tp1:eGFP;kdrl:mCherry)* (e) control and (f) ablated hearts. Arrow - Endocardial *tp1*:eGFP expression. (g) DAPT-treated 96 hpt *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* ablated ventricles. Dashed line - atrioventricular boundary. (h) Recovery of 96 hpt control and DAPT-treated *Tg(vmhc:mCherry-NTR;amhc:CreERT2;β-act2:RSG)* ablated fish. (i--l) *notch1b* and (m--p) *deltaD in situ* hybridization on (i, k, m, o) control or (j, l, n, p) ablated *Tg(vmhc:mCherry-NTR)* hearts (dashed lines) at 24 hpt. (k, l, o, p) DAPT-treated. A - atrium; AVC - atrioventricular canal; OFT - outflow tract; V - ventricle.](nihms484742f4){#F4}
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